The combination of regorafenib 80 mg plus nivolumab had a manageable safety profile and encouraging antitumor activity in patients with gastric and colorectal cancer, which warrants additional investigations in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Fukuoka et al. (2020) studied this question.